High tPA-expression in primary melanoma of the limb correlates with good prognosis

To investigate whether the course of primary melanoma disease correlates with expression of the various components of the proteolytic plasminogen activation (PA) system, immunohistochemical stainings for activators of plasminogen (tissue type (tPA) and urokinase type (uPA)), inhibitors of plasminogen activation (type 1 (PAI-I) and type 2 (PAI-2)) and the receptor for uPA (uPAR) were performed on 214 routinely processed melanoma lesions. All lesions were primary cutaneous melanomas, minimally 1.5 mm thick, and derived from patients with only local disease at the moment of diagnosis (clinically stage II (T3-4 NoMo), American Joint Committee on Cancer). Median patient follow-up was 6.1 years. Single variables as immunohistochemical staining results (extent of tumour cell staining, pattern of tumour cell staining and for some components also staining of stromal cells), histopathological and clinical parameters as well as treatment variables were analysed in order to assess their prognostic importance, in terms of time to recurrence, time to distant metastasis and duration of survival. The extent of tPA tumour cell positivity, categorized as 0-5%, 6-50% and 51-100%, appeared to be of importance for these endpoints. Lesions with 51-100% tPA-positive tumour cells were found to have the best prognosis, whereas lesions with 6-50% tPA-positive tumour cells had the worst. Moreover, the prognostic significance of Breslow thickness, microscopic ulceration and sex was confirmed in this study. Multivariate analyses, incorporating these relevant factors, showed that the extent of tPA tumour cell positivity was an independent prognostic factor for distant metastasis-free interval (P = 0.012) and for the duration of survival (P = 0.043). (C) 2000 Cancer Research Campaign.

[1]  A. Eggermont,et al.  Angiostatin generation by human tumor cell lines: Involvement of plasminogen activators , 2000, International journal of cancer.

[2]  M. Duffy,et al.  Urokinase plasminogen activator: A prognostic marker in multiple types of cancer , 1999, Journal of surgical oncology.

[3]  J. Foekens,et al.  Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer , 1999, British Journal of Cancer.

[4]  C. Sweep,et al.  Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue , 1999, British Journal of Cancer.

[5]  H. Engelberg Actions of heparin that may affect the malignant process , 1999, Cancer.

[6]  G. V. van Muijen,et al.  Markers of melanocytic tumour progression , 1998, The Journal of pathology.

[7]  M. Schmitt,et al.  Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). , 1998, International journal of oncology.

[8]  M. Carcangiu,et al.  Plasminogen activator inhibitor‐1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients , 1998, International journal of cancer.

[9]  G. V. van Muijen,et al.  Proteases in cutaneous melanoma. , 1998, Annals of medicine.

[10]  A. Eggermont,et al.  Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, a , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  B. Nielsen,et al.  Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. , 1998, European journal of cancer.

[12]  T. Kooistra,et al.  Effect of steroid hormones and retinoids on the formation of capillary-like tubular structures of human microvascular endothelial cells in fibrin matrices is related to urokinase expression , 1998 .

[13]  J. Biggerstaff,et al.  Hemostasis and Malignancy , 1998, Seminars in thrombosis and hemostasis.

[14]  D. Ruiter,et al.  Epitopes of Components of the Plasminogen Activation System are Re-exposed in Formalin-fixed Paraffin Sections by Different Retrieval Techniques , 1998 .

[15]  T. Taguchi,et al.  The expression of urokinase type plasminogen activator is a novel prognostic factor in dukes B and C colorectal cancer. , 1998, Oncology reports.

[16]  K. Nakanishi,et al.  Urokinase‐type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma , 1998 .

[17]  W. Anderson,et al.  Ability of retroviral transduction to modify the angiogenic characteristics of RPE cells , 1998, Graefe's Archive for Clinical and Experimental Ophthalmology.

[18]  M. Carcangiu,et al.  Expression of plasminogen activator inhibitor‐2 in epithelial ovarian cancer: A favorable prognostic factor related to the actions of CSF‐1 , 1997, International journal of cancer.

[19]  H. Gabbert,et al.  Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  T. Hattori,et al.  Cellular localization of urokinase‐type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues , 1997, The Journal of pathology.

[21]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[22]  B. Skov,et al.  Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry. , 1997, Lung cancer.

[23]  T. Taguchi,et al.  Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer. , 1997, Anticancer research.

[24]  A. Geurts-Moespot,et al.  A Sensitive and Robust Assay for Urokinase and Tissue-Type Plasminogen Activators (Upa and Tpa) and Their Inhibitor Type I (Pai-1) in Breast Tumor Cytosols , 1997, The International journal of biological markers.

[25]  T. Huber,et al.  Tissue plasminogen activator increases canine endothelial cell proliferation rate through a plasmin-independent, receptor-mediated mechanism. , 1996, The Journal of surgical research.

[26]  D. Rifkin,et al.  Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. , 1996, Cancer research.

[27]  J. Folkman,et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.

[28]  G. V. van Muijen,et al.  The plasminogen activation system in melanoma cell lines and in melanocytic lesions. , 1996, Melanoma research.

[29]  C. V. D. van de Velde,et al.  Prognostic value of the plasminogen activation system in patients with gastric carcinoma , 1996, Cancer.

[30]  G. Meadows,et al.  Differences in expression of metalloproteinases and plasminogen activators in murine melanocytes and B16 melanoma variants: Lack of association with In vitro invasion , 1995, International journal of cancer.

[31]  A. Nonomura,et al.  Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer. , 1995, Oncology.

[32]  E. Hedley‐Whyte,et al.  Prognostic role of urokinase-type plasminogen activator in human gliomas. , 1995, The American journal of pathology.

[33]  M. Ogawa,et al.  Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. , 1995, Surgery.

[34]  P. Quax,et al.  Components of the plasminogen activation system in uveal melanoma—a clinico‐pathological study , 1995, The Journal of pathology.

[35]  H. Kobayashi,et al.  Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. , 1994, Cancer research.

[36]  G. Hu,et al.  Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Duffy,et al.  Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer , 1994, The Lancet.

[38]  J. Saurat,et al.  Plasminogen activation in melanocytic neoplasia. , 1994, Cancer research.

[39]  A. Nakao,et al.  Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. , 1993, The American journal of gastroenterology.

[40]  M. Ogawa,et al.  Industrial preparation of poly(vinyl chloride). , 1975, British Journal of Cancer.

[41]  K. Kohno,et al.  Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro. , 1993, Experimental cell research.

[42]  M. Kramer,et al.  Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. , 1992, Experimental cell research.

[43]  P. Quax,et al.  Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation , 1991, The Journal of cell biology.

[44]  M. Ploug,et al.  Cell‐induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2‐terminal domain of the urokinase receptor , 1991, FEBS letters.

[45]  F. Jänicke,et al.  Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer , 1991, Seminars in thrombosis and hemostasis.

[46]  M. Cardinali,et al.  Interaction of fibrinogen with murine melanoma cells: covalent association with cell membranes and protection against recognition by lymphokine-activated killer cells. , 1990, Cancer research.

[47]  Y. Gunji,et al.  Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells. , 1988, Cancer research.

[48]  M. Duffy,et al.  Tissue-type plasminogen activator, a new prognostic marker in breast cancer. , 1988, Cancer research.

[49]  G. Markus The Role of Hemostasis and Fibrinolysis in the Metastatic Spread of Cancer , 1984, Seminars in thrombosis and hemostasis.

[50]  F. Rickles,et al.  Activation of blood coagulation in cancer: Trousseau's syndrome revisited. , 1983, Blood.

[51]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[52]  R. Fisher,et al.  Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression. , 1998, Oncology research.

[53]  H. Koyama,et al.  Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  S. Ehrenforth,et al.  Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer. , 1997, Cancer detection and prevention.

[55]  M. Duffy,et al.  Plasminogen activator inhibitor type 2 in breast cancer. , 1997, British Journal of Cancer.

[56]  B. M. Mueller Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. , 1996, Current topics in microbiology and immunology.

[57]  P. Quax,et al.  Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. , 1994, The American journal of pathology.

[58]  D. Cox Regression Models and Life-Tables , 1972 .